Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD [Phase 2]

View source ↗

Summary

A Phase 2 study to evaluate the efficacy and safety of IBI302 in patients with neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• IBI302

Snippet

Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: RECRUITING